ReferenceID 2831
Schisandrol A Exhibits Estrogenic Activity via Estrogen Receptor α-Dependent Signaling Pathway in Estrogen Receptor-Positive Breast Cancer Cells
Pharmaceutics
The aim of this study was to examine the estrogen-like effects of gentiopicroside, macelignan, gamma-mangostin, and three lignans (schisandrol A, schisandrol B, and schisandrin C), and their possible mechanism of action.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 2831
- Evidence Id
- 19421
- Core Evidence Id
- 19421
- Source Reference Id
- 5654
- Herb2 Reference Id
- HBREF006451
- Subject Paper Key
- HBIN043330_34371773
- Pubmed Id
- 34371773
- Doi
- 10.3390/pharmaceutics13071082
- Paper Title
- Schisandrol A Exhibits Estrogenic Activity via Estrogen Receptor α-Dependent Signaling Pathway in Estrogen Receptor-Positive Breast Cancer Cells
- Paper Abstract
- The aim of this study was to examine the estrogen-like effects of gentiopicroside, macelignan, gamma-mangostin, and three lignans (schisandrol A, schisandrol B, and schisandrin C), and their possible mechanism of action. Their effects on the proliferation of the estrogen receptor (ER)-positive breast cancer cell line (MCF-7) were evaluated using Ez-Cytox reagents. The expression of extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K), AKT, and estrogen receptor alpha (ERalpha) was measured by performing Western blot analysis. 17beta-estradiol (E2), also known as estradiol, is an estrogen steroid and was used as a positive control. ICI 182,780 (ICI), an ER antagonist, was used to block the ER function. Our results showed that, except for gentiopicroside, all the compounds promoted proliferation of MCF-7 cells, with schisandrol A being the most effective; this effect was better than that of E2 and was mitigated by ICI. Consistently, the expression of ERK, PI3K, AKT, and ERalpha increased following treatment with schisandrol A; this effect was slightly better than that of E2 and was mitigated by ICI. Taken together, the ERalpha induction via the PI3K/AKT and ERK signaling pathways may be a potential mechanism underlying the estrogen-like effects of schisandrol A. This study provides an experimental basis for the application of schisandrol A as a phytoestrogen for the prevention of menopausal symptoms.
- Journal
- Pharmaceutics
- Publish Year
- 2021
- Experiment Subject
- Experiment Type
- Cell Experiment
- Phenotype Related
- Breast Cancer
- Paper Title Cn
- Paper Title En
- Schisandrol A Exhibits Estrogenic Activity via Estrogen Receptor α-Dependent Signaling Pathway in Estrogen Receptor-Positive Breast Cancer Cells
- Bilingual Status
- semi_complete